Skip to main content
Menu
US

AlphaLISA Human FcRn Binding Kit, 5,000 Assay Points

The AlphaLISA human FcRn binding kit is designed for the detection of binding between FcRn and human IgG using a homogeneous AlphaLISA assay (no wash steps). This assay can facilitate the design and development of antibody therapeutics using a competition assay format.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Feature Specification
Application Protein-Protein Interaction
Sample Volume 10 µL

The AlphaLISA human FcRn binding kit is designed for the detection of binding between FcRn and human IgG using a homogeneous AlphaLISA assay (no wash steps). This assay can facilitate the design and development of antibody therapeutics using a competition assay format.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Product Variants
Unit Size: 500 Assay Points
Part #:
AL3095C
List Price
USD 3,338.00
Unit Size: 5,000 Assay Points
Part #:
AL3095F
List Price
USD 16,680.00

Overview

This kit is designed for the detection of binding between FcRn (neonatal Fc receptor) and human IgG using a homogeneous AlphaLISA assay (no wash steps). This assay can facilitate the design and development of antibody therapeutics using a competition assay format.

AlphaLISA features:

  • No-wash steps, no separation steps
  • Ease-of-use: few addition steps, fast assay development
  • Broad range of affinities: detect strong or weak interactions, from pM to mM affinity
  • Distance: measure very large protein or antibody complexes – spanning up to 200 nm or more
  • High avidity: multiple binding sites on each bead enables use of nanomolar concentrations of antibodies or proteins, as well as use of low affinity binders

Human FcRn also known as Neonatal Fc receptor is a heterodimer of FCGRT (Fc Fragment of IgG Receptor and Transporter) and B2M (beta 2 microglobulin). Among several Fc receptors known to interact with IgG antibodies, FcRn plays a critical role in maintaining IgG homeostasis. After IgG binds to its target on the cell surface, it is pinocytozed to the endosome where FcRn binds to the antibodies at acidic pH (6.0) and recycles the antibodies back into circulation at physiological pH (7.4). The pH dependency of FcRn binding comes mostly from histidine residues His 310, His 435, and His 436 of IgG, which are protonated at pH 6 creating a strong interaction with the anionic pocket of FcRn; they are neutralized at pH 7.4 releasing IgG from FcRn. As a result, antibodies can be protected from lysosomal degradation, leading to enhanced in vivo stability and efficacy. Hence, profiling of FcRn binding is commonly required by regulatory agencies.

AlphaLISA detection of FcRn and IgG binding uses human IgG AlphaLISA™ Acceptor beads and Streptavidin-coated Donor beads to capture biotinylated human Fc receptor. Donor beads and Acceptor beads come into proximity through IgG Fc fragment binding to FcRn. Excitation of the Donor beads provokes the release of singlet oxygen that triggers a cascade of energy transfer reactions in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Specifications

Application
Protein-Protein Interaction
Automation Compatible
Yes
Brand
AlphaLISA
Detection Modality
Alpha
Product Group
Kit
Sample Volume
10 µL
Shipping Conditions
Shipped in Blue Ice
Target Class
Binding Assay
Target Species
Human
Technology
Alpha
Unit Size
5,000 Assay Points

Image gallery

Video gallery

Resources

Are you looking for resources, click on the resource type to explore further.

1-1 of 1 Resources
Whitepaper Icon
Whitepaper
Exploring the strengths, challenges, and therapeutic applications of multispecific antibodies

Unlock the future of therapeutics with multispecific antibodies

Discover the groundbreaking advancements in multispecific antibody...

Scroll Icon